看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
1 d f9 K, u) Z; v
2 v( v Y4 t! b5 w3 ]
( v7 |+ W9 T9 g0 b/ ^Currently available feasibility data for possible combination strategies.
6 L3 U6 h( d& V3 P% w: b) A6 w————————————————————————————————! J7 c, D4 Q h! P u
Combination Feasibility according to preliminary data
3 p9 _& j, f: y——————————————————————————————————& w# c2 x% b# b4 P* Y! S( M
Bevacizumab + sorafenib Yes, reduced dose
+ @9 {) i" u' Y" R) Q: ZBevacizumab + sunitinib† No * q9 F& q4 K. H! d, B; r1 R
Bevacizumab + temsirolimus Yes + i: J$ I8 w' Z/ }+ t0 h6 N: m5 l
Bevacizumab + everolimus Yes
: p+ L2 h+ Q$ K$ C: P# C6 x2 D. \" ~Sorafenib + sunitinib ?
* a z$ `" V( m% E; wSorafenib + temsirolimus Yes, reduced dose 3 B1 ~$ m, J# t$ A' t6 u5 ]
Sorafenib + everolimus Yes, reduced dose
9 E* c* Q- z0 ^3 OSunitinib + temsirolimus† No " p. d2 H0 {" K& y
Sunitinib + everolimus ?
' k7 Q8 g( c( ?: a; MTemsirolimus + everolimus ? . x- O9 E/ r8 O7 t) O) t, b
————————————————————
4 `7 u O# T2 E/ u†Led to US FDA warning.# R& x' p" `; T& k
?: As yet unattempted combination.. [( |0 @7 `! T! o z8 m h% p2 k7 o
|